Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6989)
All Articles published online
|
Publishing Process of This Article
|
Dec 28, 2024 (publication date) through Sep 9, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Singh A, Sohal A, Batta A. GLP-1, GIP/GLP-1, and GCGR/GLP-1 receptor agonists: Novel therapeutic agents for metabolic dysfunction-associated steatohepatitis. World J Gastroenterol 2024; 30(48): 5205-5211 [PMID: 39735270 DOI: 10.3748/wjg.v30.i48.5205] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v30/i48/5205.htm |
| Number | Citing Articles |
| 1 |
Shujun Li, Nanqu Huang, Mei Wang, Wendi Huang, Yong Luo, Juan Huang. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development. Frontiers in Pharmacology 2025; 16 doi: 10.3389/fphar.2025.1610512
|
| 2 |
Yilmaz Gunes. A brief approach to hypertension in type 2 diabetes mellitus. Exploration of Endocrine and Metabolic Diseases 2025; doi: 10.37349/eemd.2025.101422
|
| 3 |
Piotr Olejnik, Kaja Kasarełło, Renata Podkowińska-Polak, Aleksandra Golenia. Psoriasis: an emerging risk factor for ischemic stroke?. Frontiers in Neurology 2025; 16 doi: 10.3389/fneur.2025.1599978
|
| 4 |
Amirmohammad Abolhassani, Mohammed H. Moghadasian, Niloofar Sedaghatnezhad, Sadegh Jafarnejad. Anti-Dyslipidemic, Anti-Hypertensive, and Glycemic Control Effects of Akkermansia Muciniphila: Lesser-Known Benefits in Metabolic Syndrome – A Narrative Review. Heart and Mind 2025; doi: 10.4103/hm.HM-D-24-00161
|
| 5 |
Junyu Wang, Jingting Lei, Martin C. Harmsen, Han Moshage. From cooperation to collapse: systemic failure in liver disease through a sociological lens. Exploration of Digestive Diseases 2025; 4 doi: 10.37349/edd.2025.100580
|
| 6 |
Natalie Eppler, Elizabeth Jones, Forkan Ahamed, Yuxia Zhang. Multifaceted Human Antigen R (HuR): A Key Player in Liver Metabolism and MASLD. Livers 2025; 5(3): 33 doi: 10.3390/livers5030033
|
| 7 |
Anna Giannakogeorgou, Michael Roden, Kalliopi Pafili. Diabetes mellitus as a multisystem disease: understanding subtypes, complications, and the link with steatotic liver diseases in humans. Hormones 2025; doi: 10.1007/s42000-025-00701-y
|
| 8 |
Xinyi Zhang, Nanqin Peng, Xiaoyue Zhang, Zicheng Zhu, Yan Miao, Yuting Wu, Jitao Ling, Chen Li, Wenli Gu, Jing Zhang, Abudukeremu Ayiguli, Ziheng Zheng, Peng Yu, Xiao Liu. Association of glucagon-like peptide-1 receptor agonists with atrial fibrillation, cardiac arrest, and ventricular fibrillation: Casual evidence from a drug target Mendelian randomization. Diabetology & Metabolic Syndrome 2025; 17(1) doi: 10.1186/s13098-025-01712-w
|
| 9 |
A. Pariente. Hépatopathies stéatosiques dysmétaboliques. EMC - Traité de médecine AKOS 2025; 28(3): 1 doi: 10.1016/S1634-6939(25)49520-9
|
| 10 |
Stefano Fiorucci, Ginevra Urbani. Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives. Expert Opinion on Investigational Drugs 2025; : 1 doi: 10.1080/13543784.2025.2546812
|
| 11 |
Pranav Patel. Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease. Journal of Clinical Medicine 2025; 14(17): 6060 doi: 10.3390/jcm14176060
|
| 12 |
Xing Wan, Jingyuan Ma, He Bai, Xuyang Hu, Yanna Ma, Mingjian Zhao, Jifeng Liu, Zhijun Duan. Drug Advances in NAFLD: Individual and Combination Treatment Strategies of Natural Products and Small-Synthetic-Molecule Drugs. Biomolecules 2025; 15(1): 140 doi: 10.3390/biom15010140
|
| 13 |
Adam Vašura, Evžen Machytka, Marek Bužga, Jitka Macháčková, Jan Král. The significance of metabolism-associated steatotic liver disease and its treatment. Vnitřní lékařství 2025; 71(1): 29 doi: 10.36290/vnl.2025.005
|